CN111658824A - 一种具有协同抗凝及抗钙化功能的瓣膜材料及其制备方法 - Google Patents
一种具有协同抗凝及抗钙化功能的瓣膜材料及其制备方法 Download PDFInfo
- Publication number
- CN111658824A CN111658824A CN202010541893.6A CN202010541893A CN111658824A CN 111658824 A CN111658824 A CN 111658824A CN 202010541893 A CN202010541893 A CN 202010541893A CN 111658824 A CN111658824 A CN 111658824A
- Authority
- CN
- China
- Prior art keywords
- valve
- calcification
- functions
- anticoagulation
- valve material
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000463 material Substances 0.000 title claims abstract description 103
- 230000010100 anticoagulation Effects 0.000 title claims abstract description 29
- 239000012528 membrane Substances 0.000 title claims abstract description 23
- 230000002195 synergetic effect Effects 0.000 title claims abstract description 22
- 238000002360 preparation method Methods 0.000 title claims abstract description 13
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 claims abstract description 39
- 238000004132 cross linking Methods 0.000 claims abstract description 36
- 238000000034 method Methods 0.000 claims abstract description 22
- 230000002308 calcification Effects 0.000 claims abstract description 15
- 238000007789 sealing Methods 0.000 claims abstract description 15
- 239000003146 anticoagulant agent Substances 0.000 claims abstract description 12
- 229940127219 anticoagulant drug Drugs 0.000 claims abstract description 11
- 238000004140 cleaning Methods 0.000 claims abstract description 8
- 239000003431 cross linking reagent Substances 0.000 claims abstract description 8
- -1 amino compound Chemical class 0.000 claims abstract description 7
- 241001465754 Metazoa Species 0.000 claims abstract description 6
- 239000000243 solution Substances 0.000 claims description 26
- 210000004379 membrane Anatomy 0.000 claims description 21
- 238000006243 chemical reaction Methods 0.000 claims description 11
- 210000003516 pericardium Anatomy 0.000 claims description 9
- 150000001875 compounds Chemical class 0.000 claims description 8
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 claims description 6
- 239000007853 buffer solution Substances 0.000 claims description 6
- NAQMVNRVTILPCV-UHFFFAOYSA-N hexane-1,6-diamine Chemical compound NCCCCCCN NAQMVNRVTILPCV-UHFFFAOYSA-N 0.000 claims description 6
- 241000283690 Bos taurus Species 0.000 claims description 5
- 229920001661 Chitosan Polymers 0.000 claims description 5
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 claims description 4
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 claims description 4
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 4
- 150000001412 amines Chemical class 0.000 claims description 4
- 229920000669 heparin Polymers 0.000 claims description 4
- 229960002897 heparin Drugs 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 4
- 210000000813 small intestine Anatomy 0.000 claims description 4
- 210000004876 tela submucosa Anatomy 0.000 claims description 4
- AHYRFXNQAGYFAP-UHFFFAOYSA-M C(C)S(=O)(=O)[O-].[Na+].N1CCOCC1 Chemical compound C(C)S(=O)(=O)[O-].[Na+].N1CCOCC1 AHYRFXNQAGYFAP-UHFFFAOYSA-M 0.000 claims description 3
- 229920002971 Heparan sulfate Polymers 0.000 claims description 3
- 102000007625 Hirudins Human genes 0.000 claims description 3
- 108010007267 Hirudins Proteins 0.000 claims description 3
- 229920002873 Polyethylenimine Polymers 0.000 claims description 3
- 108010039918 Polylysine Proteins 0.000 claims description 3
- WQPDUTSPKFMPDP-OUMQNGNKSA-N hirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(OS(O)(=O)=O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N2)=O)CSSC1)C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)CSSC1)C(C)C)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 WQPDUTSPKFMPDP-OUMQNGNKSA-N 0.000 claims description 3
- 229940006607 hirudin Drugs 0.000 claims description 3
- 229920000724 poly(L-arginine) polymer Polymers 0.000 claims description 3
- 108010011110 polyarginine Proteins 0.000 claims description 3
- 229920000656 polylysine Polymers 0.000 claims description 3
- 239000002904 solvent Substances 0.000 claims description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 3
- LGLMLRNXJDSTMP-UHFFFAOYSA-N Cc1ccc(cc1)S(O)(=O)=O.N=C=NC(CN1CCOCC1)C1CCCCC1 Chemical compound Cc1ccc(cc1)S(O)(=O)=O.N=C=NC(CN1CCOCC1)C1CCCCC1 LGLMLRNXJDSTMP-UHFFFAOYSA-N 0.000 claims description 2
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 claims description 2
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 2
- 239000000565 sealant Substances 0.000 claims 1
- 125000003172 aldehyde group Chemical group 0.000 abstract description 12
- 208000007536 Thrombosis Diseases 0.000 abstract description 9
- 210000002073 venous valve Anatomy 0.000 abstract description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 abstract description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 abstract description 4
- 210000003102 pulmonary valve Anatomy 0.000 abstract description 4
- 210000001765 aortic valve Anatomy 0.000 abstract description 3
- 239000012295 chemical reaction liquid Substances 0.000 abstract description 3
- 210000004115 mitral valve Anatomy 0.000 abstract description 3
- 210000000591 tricuspid valve Anatomy 0.000 abstract description 3
- 150000001299 aldehydes Chemical group 0.000 abstract description 2
- 230000015572 biosynthetic process Effects 0.000 abstract description 2
- 239000012046 mixed solvent Substances 0.000 abstract description 2
- 238000005520 cutting process Methods 0.000 description 5
- 230000008021 deposition Effects 0.000 description 4
- 210000001147 pulmonary artery Anatomy 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 239000000835 fiber Substances 0.000 description 3
- 238000002513 implantation Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- AXKJZKYQHIYVRK-UHFFFAOYSA-N N'-ethylmethanediimine 4-methylbenzenesulfonic acid Chemical compound CCN=C=N.CC1=CC=C(S(O)(=O)=O)C=C1 AXKJZKYQHIYVRK-UHFFFAOYSA-N 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 229920000768 polyamine Polymers 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 239000007987 MES buffer Substances 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 239000002262 Schiff base Substances 0.000 description 1
- 150000004753 Schiff bases Chemical class 0.000 description 1
- 210000004712 air sac Anatomy 0.000 description 1
- RGCKGOZRHPZPFP-UHFFFAOYSA-N alizarin Chemical compound C1=CC=C2C(=O)C3=C(O)C(O)=CC=C3C(=O)C2=C1 RGCKGOZRHPZPFP-UHFFFAOYSA-N 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000005238 degreasing Methods 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 210000003492 pulmonary vein Anatomy 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 230000001360 synchronised effect Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3604—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel
- A61L27/3625—Vascular tissue, e.g. heart valves
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3604—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3604—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel
- A61L27/3629—Intestinal tissue, e.g. small intestinal submucosa
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3641—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the site of application in the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3683—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment
- A61L27/3687—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment characterised by the use of chemical agents in the treatment, e.g. specific enzymes, detergents, capping agents, crosslinkers, anticalcification agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/507—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials for artificial blood vessels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/54—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L33/00—Antithrombogenic treatment of surgical articles, e.g. sutures, catheters, prostheses, or of articles for the manipulation or conditioning of blood; Materials for such treatment
- A61L33/0005—Use of materials characterised by their function or physical properties
- A61L33/0011—Anticoagulant, e.g. heparin, platelet aggregation inhibitor, fibrinolytic agent, other than enzymes, attached to the substrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L33/00—Antithrombogenic treatment of surgical articles, e.g. sutures, catheters, prostheses, or of articles for the manipulation or conditioning of blood; Materials for such treatment
- A61L33/0005—Use of materials characterised by their function or physical properties
- A61L33/0011—Anticoagulant, e.g. heparin, platelet aggregation inhibitor, fibrinolytic agent, other than enzymes, attached to the substrate
- A61L33/0041—Anticoagulant, e.g. heparin, platelet aggregation inhibitor, fibrinolytic agent, other than enzymes, attached to the substrate characterised by the choice of an antithrombatic agent other than heparin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L33/00—Antithrombogenic treatment of surgical articles, e.g. sutures, catheters, prostheses, or of articles for the manipulation or conditioning of blood; Materials for such treatment
- A61L33/0076—Chemical modification of the substrate
- A61L33/0082—Chemical modification of the substrate by reacting with an organic compound other than heparin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L33/00—Antithrombogenic treatment of surgical articles, e.g. sutures, catheters, prostheses, or of articles for the manipulation or conditioning of blood; Materials for such treatment
- A61L33/06—Use of macromolecular materials
- A61L33/08—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L33/00—Antithrombogenic treatment of surgical articles, e.g. sutures, catheters, prostheses, or of articles for the manipulation or conditioning of blood; Materials for such treatment
- A61L33/06—Use of macromolecular materials
- A61L33/12—Polypeptides, proteins or derivatives thereof, e.g. degradation products thereof
- A61L33/128—Other specific proteins or polypeptides not covered by A61L33/122 - A61L33/126
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0697—Artificial constructs associating cells of different lineages, e.g. tissue equivalents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/23—Carbohydrates
- A61L2300/232—Monosaccharides, disaccharides, polysaccharides, lipopolysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/23—Carbohydrates
- A61L2300/236—Glycosaminoglycans, e.g. heparin, hyaluronic acid, chondroitin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/252—Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/418—Agents promoting blood coagulation, blood-clotting agents, embolising agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/42—Anti-thrombotic agents, anticoagulants, anti-platelet agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2400/00—Materials characterised by their function or physical properties
- A61L2400/02—Treatment of implants to prevent calcification or mineralisation in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2400/00—Materials characterised by their function or physical properties
- A61L2400/18—Modification of implant surfaces in order to improve biocompatibility, cell growth, fixation of biomolecules, e.g. plasma treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/20—Materials or treatment for tissue regeneration for reconstruction of the heart, e.g. heart valves
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/40—Preparation and treatment of biological tissue for implantation, e.g. decellularisation, cross-linking
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Transplantation (AREA)
- Molecular Biology (AREA)
- Botany (AREA)
- Zoology (AREA)
- Surgery (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Materials Engineering (AREA)
- Vascular Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Organic Chemistry (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Materials For Medical Uses (AREA)
- Prostheses (AREA)
Abstract
本发明提供了一种具有协同抗凝及抗钙化功能的瓣膜材料及其制备方法，其制备方法包括以下步骤：对动物源生物瓣膜材料进行戊二醛交联处理；将处理后的瓣膜材料浸入含有胺基化合物的封闭液中处理0.5‑6h，进而封闭戊二醛交联后残留的醛基基团；然后瓣膜材料放入含有抗凝剂和交联剂的反应液中，于4℃‑37℃条件下交联处理6‑24h；最后对瓣膜材料进行清洗，制得，将瓣膜材料保存于戊二醛或异丙醇/丙三醇的混合溶剂中。该方法可有效解决现有方法制得的瓣膜材料存在的由于醛基残留引发的易钙化和形成血栓的问题，按照本方法制得的瓣膜材料可用作于主动脉瓣、肺动脉瓣、静脉瓣、二尖瓣及三尖瓣置换术所需的瓣膜材料。
Description
技术领域
本发明属于生物医用材料及医疗器械改性技术领域，具体涉及一种具有协同抗凝及抗钙化功能的瓣膜材料及其制备方法，按照本方法制得的瓣膜材料可用作于主动脉瓣、肺动脉瓣、静脉瓣、二尖瓣及三尖瓣置换术所需的瓣膜材料。
背景技术
经导管介入瓣膜治疗手段正成为瓣膜置换术中的主流方向，目前与之相对发展的技术则包括主动脉瓣、肺动脉瓣、二尖瓣、三尖瓣及静脉瓣置换术等。目前主流用于介入瓣膜术的瓣膜材料为异种生物瓣膜材料，主要是来源于猪心包、牛心包、小肠粘膜下层及鱼鳔等。通过对动物来源的瓣膜材料进行化学交联，可以提升材料的力学强度和使用寿命，目前较为成熟的商业化交联手段多数是基于戊二醛的交联方法，而猪心包和牛心包膜经戊二醛交联后的材料也已经广泛投入市场使用。
介入瓣膜置换术，对于生物瓣膜材料有着较为特殊的需求，主要包括力学性能、热收缩温度、流体力学性能、抗钙化、抗凝血需求等。从瓣膜材料本身角度，抗钙化性能几乎是所有瓣膜材料必须具备的功能，也是提升瓣膜服役寿命的有效保障。其中对于静脉瓣和肺动脉瓣而言，由于其血流环境较为复杂，且流通血液为流速较慢且易凝的静脉血，因此，对瓣膜材料的抗血栓性能要求也格外突出。尽管戊二醛交联瓣膜存在诸多不足，如醛基残留引发的钙化和细胞毒性及致血栓风险，它依旧是目前商业生物瓣膜采取的主流方式。诸多新型交联方法的同步发展有望成为替代戊二醛的方案，然而目前受限于瓣膜灭菌、灭毒工艺及保存工艺上的挑战，新型交联瓣膜离商业化还有一定的距离。因此，针对肺动脉瓣和静脉瓣在临床应用中需要提高瓣膜材料抗钙化和抗血栓性能的迫切需求，开发具有优良抗凝血和抗钙化性能的肺动脉/静脉瓣膜材料，具有极大的临床应用和市场价值。
发明内容
针对现有技术中存在的上述问题，本发明提供一种具有协同抗凝及抗钙化功能的瓣膜材料及其制备方法，该方法可有效解决现有方法制得的瓣膜材料存在的由于醛基残留引发的易钙化和形成血栓的问题，按照本方法制得的瓣膜材料可用作于主动脉瓣、肺动脉瓣、静脉瓣、二尖瓣及三尖瓣置换术所需的瓣膜材料。
为实现上述目的，本发明解决其技术问题所采用的技术方案是：
一种具有协同抗凝及抗钙化功能的瓣膜材料的制备方法，包括以下步骤：
(1)对动物源生物瓣膜材料进行戊二醛交联处理，使得瓣膜材料可以长久抗腐败；
(2)将步骤(1)中处理后的瓣膜材料浸入胺基化合物封闭液中处理0.5-6h，进而封闭戊二醛交联后残留的醛基基团；
(3)将步骤(2)中处理后的瓣膜材料放入含有抗凝剂和交联剂的反应液中，于4℃-37℃条件下交联处理6-24h；
(4)对步骤(3)中处理后的瓣膜材料进行清洗，制得，然后将瓣膜材料保存于戊二醛或异丙醇/丙三醇的混合溶剂中。
进一步地，所述动物源生物瓣膜材料包括猪心包膜、牛心包膜、小肠粘膜下层中一种。
进一步地，步骤(1)中戊二醛的浓度为0.3％-3％，交联处理时间为24-96h，交联pH值6-9。
进一步地，步骤(1)中戊二醛的浓度为1％，交联处理时间为72h，交联pH值7。
进一步地，步骤(1)中戊二醛交联方式包括一步交联、多步交联和浓度梯度交联，交联用的溶剂为水、PBS或其他盐离子缓冲液。
进一步地，步骤(2)中的胺基化合物上携带有至少3个伯氨基基团。
进一步地，步骤(2)中的胺基化合物包括聚乙烯亚胺、壳聚糖、羧甲基壳聚糖、多聚赖氨酸、多聚精氨酸和己二胺中的一种，胺基化合物封闭液的浓度为0.1-100mg/mL。
进一步地，步骤(2)中胺基化合物在封闭液中的浓度为10mg/mL。
进一步地，步骤(3)中抗凝化合物包括肝素、硫酸乙酰肝素、比伐芦丁和水蛭素。
进一步地，步骤(3)中交联剂包括1-乙基-(3-二甲基氨基丙基)碳二亚胺盐酸盐)/N-羟基琥珀酰亚胺、1-环已基-2-吗啉乙基碳二亚胺对甲苯磺酸盐和N,N'- 二环己基碳二亚胺中的一种。
进一步地，步骤(3)中反应液中的溶剂包括水、吗啉乙磺酸钠盐溶液和PBS 缓冲液。
进一步地，步骤(3)反应液中抗凝剂的浓度为0.2mg/mL-20mg/mL，抗凝剂与交联剂的摩尔比为0.2-5:0.2-2。
进一步地，步骤(3)反应液中抗凝剂的浓度为5mg/mL，抗凝剂与交联剂的摩尔比为0.3：2。
通过上述的方法制备得到具有协同抗凝及抗钙化功能的瓣膜材料。
本发明产生的有益效果为：
在瓣膜中通过两步放大效应，制备了具有协同抗钙化及抗凝功能的瓣膜材料用作于肺动脉/静脉瓣膜。戊二醛交联的瓣膜材料是纤维取向排布且具有孔隙结构的材料，其纤维上含有醛基、羧基等基团，本发明通过灌注多胺基化合物再固定抗凝化合物的方式实现瓣膜抗凝的放大效应，为肺动脉/静脉瓣膜材料的复杂血流环境提供较好的抗血栓活性；引入多胺基化合物，通过多胺基化合物上的氨基与瓣膜材料上的醛基间的席夫碱反应直接封闭残留醛基，避免钙离子附着在残留的醛基上形成钙盐结晶，提高瓣膜材料的抗钙化能力，进而提高瓣膜的使用寿命；同时抗凝剂上的羧基可以与引入的胺基通过脱水缩合形成酰胺键，实现共价固定，进而提高瓣膜的抗凝效果。
附图说明
图1为戊二醛交联膜表面血栓沉积图；
图2为改性瓣膜材料表面血栓沉积图；
图3中左图为皮下植入3个月后，戊二醛交联瓣膜材料钙化图，右图为皮下植入3个月后改性瓣膜材料钙化图。
具体实施方式
下面结合附图对本发明的具体实施方式做详细的说明。
实施例1
一种具有协同抗凝及抗钙化功能的瓣膜材料，其制备方法包含以下步骤：
(1)将去脂后的猪心包材料切割成合适大小，绷板后浸入到浓度为1％， pH值为7的戊二醛溶液中，24小时换液处理，持续处理72小时；
(2)将步骤(1)中处理后的瓣膜材料浸入到具有含有聚乙烯亚胺 (10mg/mL)的封闭液中(pH7.4)，常温处理0.5h，封闭戊二醛交联后残留的醛基基团；
(3)将上述步骤得到的戊二醛瓣膜转移到MES缓冲液中，添加肝素 (5mg/mL)和N,N'-二环己基碳二亚胺(0.5mg/mL)，在pH5.5条件下，于4℃交联处理24h；
(4)将上述反应液处理后得到的瓣膜材料进行清洗后，得到目标瓣膜材料。
实施例2
一种具有协同抗凝及抗钙化功能的瓣膜材料，其制备方法包含以下步骤：
(1)将去脂后的猪心包材料切割成合适大小，绷板后浸入到浓度为0.5％， pH值为8.5的戊二醛溶液中处理24小时，随后转移到1％的戊二醛溶液中处理 48小时；
(2)将步骤(1)中处理后的瓣膜材料浸入到具有含有多聚赖氨酸(5mg/mL) 的封闭液中(pH7.4)，常温处理6h，封闭戊二醛交联后残留的醛基基团；
(3)将上述步骤得到的戊二醛瓣膜转移到PBS缓冲液中，添加比伐芦丁 (1mg/mL)和1-乙基-(3-二甲基氨基丙基)碳二亚胺盐酸盐(0.3mg/mL)，在pH6 条件下，于25℃交联处理4h；
(4)将上述反应液处理后得到的瓣膜材料进行清洗后，得到目标瓣膜材料。
实施例3
一种具有协同抗凝及抗钙化功能的瓣膜材料，其制备方法包含以下步骤：
(1)将去脂后的牛心包材料切割成合适大小，绷板后浸入到浓度为1％， pH值为6.5的戊二醛溶液中处理24小时，随后转移到0.5％的戊二醛溶液中处理48小时；
(2)将步骤(1)处理后瓣膜材料浸入到具有含有己二胺(4mg/mL)的封闭液中(pH7.4)，常温处理3h，封闭戊二醛交联后残留的醛基基团；
(3)将上述步骤得到的戊二醛瓣膜转移到PBS缓冲液中，添加水蛭素(2mg/mL)和1-乙基-(3-二甲基氨基丙基)碳二亚胺盐酸盐)(0.4mg/mL)，在pH5 条件下，于37℃交联处理2h；
(4)将上述反应液处理后得到的瓣膜材料进行清洗后，得到目标瓣膜材料。
实施例4
一种具有协同抗凝及抗钙化功能的瓣膜材料，其制备方法包含以下步骤：
(1)将小肠粘膜下层剥离后切割成合适大小，绷板后浸入到浓度为1％， pH值为8的戊二醛溶液中处理72小时；
(2)将瓣膜材料浸入到具有含有壳聚糖(10mg/mL)的封闭液中(pH5)，常温处理6h，封闭戊二醛交联后残留的醛基基团；
(3)将上述步骤得到的戊二醛瓣膜转移到PBS缓冲液中，添加硫酸乙酰肝素(3mg/mL)和1-环已基-2-吗啉乙基碳二亚胺对甲苯磺酸盐(0.8mg/mL)，在 pH6.5条件下，于20℃交联处理8h；
(4)将上述反应液处理后得到的瓣膜材料进行清洗后，得到目标瓣膜材料。
实施例5
一种具有协同抗凝及抗钙化功能的瓣膜材料，其制备方法包含以下步骤：
(1)将猪心包材料去脂后切割成合适大小，绷板后浸入到1％的戊二醛溶液中处理72小时；
(2)将步骤(1)中处理后的瓣膜材料浸入到具有含有多聚精氨酸(5mg/mL) 的封闭液中(pH7.4)，常温处理4h，封闭戊二醛交联后残留的醛基基团；
(3)将上述步骤得到的戊二醛瓣膜转移到吗啉乙磺酸钠盐缓冲液中，添加肝素(6mg/mL)和1-环已基-2-吗啉乙基碳二亚胺对甲苯磺酸盐(1mg/mL)，在 pH5.5条件下，于10℃交联处理20h；
(4)将上述反应液处理后得到的瓣膜材料进行清洗后，得到目标瓣膜材料。
试验例
以实施例1中制得的瓣膜为例，观察戊二醛交联后瓣膜材料表面，然后观察改性处理后兔半体血液循环试验2小时后，瓣膜表面血栓沉积情况，具体结果见图1和图2；将实施例1中戊二醛交联后的瓣膜材料和改性后的瓣膜材料分别皮下植入3个月，观察瓣膜材料钙化情况，具体见图3。
通过图1可以看出，未经改性的传统戊二醛交联工艺，其瓣膜材料上沉积了大量血栓，红细胞和大量纤维网络交错。而图2则显示，经实施例1方法中描述的抗凝改性后，瓣膜材料表面依旧光洁，无明显的血栓沉积，证实了改性瓣膜材料优异的血液相容性和抗凝血功能。
通过图3的皮下植入实验看出，3个月后，经茜素红染色，戊二醛交联膜(左) 上有明显的钙化斑点沉积，而经改性的瓣膜材料(右)依旧十分的光洁，无明显的钙化斑点，证实了材料的抗钙化性能。
Claims (10)
1.一种具有协同抗凝及抗钙化功能的瓣膜材料的制备方法，其特征在于，包括以下步骤：
(1)对动物源生物瓣膜材料进行戊二醛交联处理；
(2)将步骤(1)中处理后的瓣膜材料浸入胺基化合物封闭液中处理0.5-6h；
(3)将步骤(2)中处理后的瓣膜材料放入含有抗凝剂和交联剂的反应液中，于4℃-37℃条件下交联处理6-24h；
(4)对步骤(3)中处理后的瓣膜材料进行清洗，制得。
2.如权利要求1所述的具有协同抗凝及抗钙化功能的瓣膜材料的制备方法，其特征在于，所述动物源生物瓣膜材料包括猪心包膜、牛心包膜、小肠粘膜下层中一种。
3.如权利要求1所述的具有协同抗凝及抗钙化功能的瓣膜材料的制备方法，其特征在于，步骤(1)中戊二醛的浓度为0.3％-3％，交联处理时间为24-96h，交联pH值6-9。
4.如权利要求1所述的具有协同抗凝及抗钙化功能的瓣膜材料的制备方法，其特征在于，步骤(2)中的胺基化合物上携带有至少三个伯氨基基团。
5.如权利要求4所述的具有协同抗凝及抗钙化功能的瓣膜材料的制备方法，其特征在于，步骤(2)中的胺基化合物包括聚乙烯亚胺、壳聚糖、羧甲基壳聚糖、多聚赖氨酸、多聚精氨酸和己二胺中的一种，胺基化合物封闭液的浓度为0.1-100mg/mL。
6.如权利要求1所述的具有协同抗凝及抗钙化功能的瓣膜材料的制备方法，其特征在于，步骤(3)中抗凝化合物包括肝素、硫酸乙酰肝素、比伐芦丁和水蛭素中的一种。
7.如权利要求1所述的具有协同抗凝及抗钙化功能的瓣膜材料的制备方法，其特征在于，步骤(3)中交联剂包括1-乙基-(3-二甲基氨基丙基)碳二亚胺盐酸盐)/N-羟基琥珀酰亚胺、1-环已基-2-吗啉乙基碳二亚胺对甲苯磺酸盐和N,N'-二环己基碳二亚胺中的一种。
8.如权利要求1所述的具有协同抗凝及抗钙化功能的瓣膜材料的制备方法，其特征在于，步骤(3)中反应液中的溶剂包括水、吗啉乙磺酸钠盐溶液和PBS缓冲液。
9.如权利要求1所述的具有协同抗凝及抗钙化功能的瓣膜材料的制备方法，步骤(3)反应液中抗凝剂的浓度为0.2mg/mL-20mg/mL，抗凝剂与交联剂的摩尔比为0.2-5:0.2-2。
10.通过权利要求1-9中任一项所述的方法制备得到具有协同抗凝及抗钙化功能的瓣膜材料。
Priority Applications (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010541893.6A CN111658824B (zh) | 2020-06-15 | 2020-06-15 | 一种具有协同抗凝及抗钙化功能的瓣膜材料及其制备方法 |
| PCT/CN2021/100181 WO2021254346A1 (zh) | 2020-06-15 | 2021-06-15 | 一种具有协同抗凝及抗钙化功能的瓣膜材料及其制备方法 |
| EP21826690.6A EP4137169A4 (en) | 2020-06-15 | 2021-06-15 | VALVE MATERIAL WITH SYNERGISTIC ANTICLOTY AND ANTI-CALCIFICATION FUNCTIONS AND MANUFACTURING PROCESS THEREOF |
| US18/000,374 US20230218803A1 (en) | 2020-06-15 | 2021-06-15 | Valve Material With Combined Anti-Clotting And Anti-Calcification Properties And Preparation Method Therefor |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010541893.6A CN111658824B (zh) | 2020-06-15 | 2020-06-15 | 一种具有协同抗凝及抗钙化功能的瓣膜材料及其制备方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN111658824A true CN111658824A (zh) | 2020-09-15 |
| CN111658824B CN111658824B (zh) | 2021-03-30 |
Family
ID=72387979
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010541893.6A Active CN111658824B (zh) | 2020-06-15 | 2020-06-15 | 一种具有协同抗凝及抗钙化功能的瓣膜材料及其制备方法 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20230218803A1 (zh) |
| EP (1) | EP4137169A4 (zh) |
| CN (1) | CN111658824B (zh) |
| WO (1) | WO2021254346A1 (zh) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113769169A (zh) * | 2021-10-22 | 2021-12-10 | 四川大学华西医院 | 一种抗凝促细胞黏附生物瓣膜材料及其制备方法 |
| WO2021254346A1 (zh) * | 2020-06-15 | 2021-12-23 | 吉林启明皓月生物科技有限公司 | 一种具有协同抗凝及抗钙化功能的瓣膜材料及其制备方法 |
| CN114949347A (zh) * | 2022-05-31 | 2022-08-30 | 四川大学 | 一种改性交联生物瓣膜及其制备方法和用途 |
| CN116983477A (zh) * | 2023-08-03 | 2023-11-03 | 晨兴(南通)医疗器械有限公司 | 复合交联生物瓣膜材料的制备方法及复合交联生物瓣膜材料 |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5645587A (en) * | 1996-06-05 | 1997-07-08 | Chanda; Jyotirmay | Prevention of calcification and degeneration of biological tissue grafts for implantation in humans |
| EP1863546A2 (en) * | 2005-03-11 | 2007-12-12 | Wake Forest University Health Sciences | Production of tissue engineered heart valves |
| CN101184516A (zh) * | 2005-03-25 | 2008-05-21 | 爱德华兹生命科学公司 | 对生物假体组织进行处理以缓解植入后钙化 |
| CN101678152A (zh) * | 2007-06-11 | 2010-03-24 | 爱德华兹生命科学公司 | 用于给生物假体组织预加应力和加帽的方法 |
| CN103705980A (zh) * | 2007-12-21 | 2014-04-09 | 爱德华兹生命科学公司 | 加帽生物假体组织以减少钙化 |
| CN104623732A (zh) * | 2013-11-13 | 2015-05-20 | 中国科学院上海硅酸盐研究所 | 人工生物心脏瓣膜材料及制备方法和用途 |
| CN109651627A (zh) * | 2018-12-18 | 2019-04-19 | 中国医学科学院生物医学工程研究所 | 天然聚合物交联剂及其在制备抗钙化生物瓣膜中的应用 |
| CN109833118A (zh) * | 2018-09-29 | 2019-06-04 | 四川大学 | 一种采用交联处理提高生物瓣膜稳定性的方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4378224A (en) * | 1980-09-19 | 1983-03-29 | Nimni Marcel E | Coating for bioprosthetic device and method of making same |
| CN109260517B (zh) * | 2018-09-19 | 2020-10-30 | 杭州启明医疗器械股份有限公司 | 一种可预装干燥生物心脏瓣膜及其制备方法 |
| CN111658824B (zh) * | 2020-06-15 | 2021-03-30 | 四川大学 | 一种具有协同抗凝及抗钙化功能的瓣膜材料及其制备方法 |
-
2020
- 2020-06-15 CN CN202010541893.6A patent/CN111658824B/zh active Active
-
2021
- 2021-06-15 US US18/000,374 patent/US20230218803A1/en active Pending
- 2021-06-15 WO PCT/CN2021/100181 patent/WO2021254346A1/zh unknown
- 2021-06-15 EP EP21826690.6A patent/EP4137169A4/en active Pending
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5645587A (en) * | 1996-06-05 | 1997-07-08 | Chanda; Jyotirmay | Prevention of calcification and degeneration of biological tissue grafts for implantation in humans |
| EP1863546A2 (en) * | 2005-03-11 | 2007-12-12 | Wake Forest University Health Sciences | Production of tissue engineered heart valves |
| CN101184516A (zh) * | 2005-03-25 | 2008-05-21 | 爱德华兹生命科学公司 | 对生物假体组织进行处理以缓解植入后钙化 |
| CN101678152A (zh) * | 2007-06-11 | 2010-03-24 | 爱德华兹生命科学公司 | 用于给生物假体组织预加应力和加帽的方法 |
| CN103705980A (zh) * | 2007-12-21 | 2014-04-09 | 爱德华兹生命科学公司 | 加帽生物假体组织以减少钙化 |
| CN104623732A (zh) * | 2013-11-13 | 2015-05-20 | 中国科学院上海硅酸盐研究所 | 人工生物心脏瓣膜材料及制备方法和用途 |
| CN109833118A (zh) * | 2018-09-29 | 2019-06-04 | 四川大学 | 一种采用交联处理提高生物瓣膜稳定性的方法 |
| CN109651627A (zh) * | 2018-12-18 | 2019-04-19 | 中国医学科学院生物医学工程研究所 | 天然聚合物交联剂及其在制备抗钙化生物瓣膜中的应用 |
Non-Patent Citations (3)
| Title |
|---|
| HWAL SUH ET AL.: "Evaluation of calcification in porcine valves treated by ultraviolet ray and glutaraldehyde", 《MATERIALS SCIENCE AND ENGINEERING C》 * |
| PETER ZILLA ET AL.: "Carbodiimide Treatment Dramatically Potentiates the Anticalcific Effect of Alpha-Amino Oleic Acid on Glutaraldehyde-Fixed Aortic Wall Tissue", 《ANN THORAC SURG》 * |
| YANG LEI ET AL.: "Bioprosthetic heart valves’ structural integrity improvement through exogenous amino donor treatments", 《MATERIALS RESEARCH SOCIETY》 * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021254346A1 (zh) * | 2020-06-15 | 2021-12-23 | 吉林启明皓月生物科技有限公司 | 一种具有协同抗凝及抗钙化功能的瓣膜材料及其制备方法 |
| CN113769169A (zh) * | 2021-10-22 | 2021-12-10 | 四川大学华西医院 | 一种抗凝促细胞黏附生物瓣膜材料及其制备方法 |
| CN114949347A (zh) * | 2022-05-31 | 2022-08-30 | 四川大学 | 一种改性交联生物瓣膜及其制备方法和用途 |
| CN116983477A (zh) * | 2023-08-03 | 2023-11-03 | 晨兴(南通)医疗器械有限公司 | 复合交联生物瓣膜材料的制备方法及复合交联生物瓣膜材料 |
Also Published As
| Publication number | Publication date |
|---|---|
| EP4137169A1 (en) | 2023-02-22 |
| EP4137169A4 (en) | 2024-05-01 |
| CN111658824B (zh) | 2021-03-30 |
| WO2021254346A1 (zh) | 2021-12-23 |
| US20230218803A1 (en) | 2023-07-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111658824B (zh) | 一种具有协同抗凝及抗钙化功能的瓣膜材料及其制备方法 | |
| US5080670A (en) | Bioprosthetic valve | |
| US9782255B2 (en) | Bioprosthetic components for an implant, in particular partly crosslinked biological heart valves | |
| CA2312376C (en) | Method for inhibiting calcification of aldehyde-fixed bioprosthetic materials | |
| CN111701077B (zh) | 一种具有抗血栓抗钙化功能的瓣膜及其制备方法和应用 | |
| AU734370B2 (en) | Methods for actively binding heparin to biological and non- biological bioprosthetic material | |
| JPH0838590A (ja) | 高い耐石灰化性を有する生体由来補てつ心臓弁 | |
| WO2021239080A1 (zh) | 一种兼具抗凝血和抗钙化性能的生物瓣膜及其制备方法 | |
| CN109651627A (zh) | 天然聚合物交联剂及其在制备抗钙化生物瓣膜中的应用 | |
| CN111420120A (zh) | 一种具有抗凝血和抗钙化功能的生物瓣膜及其制备方法 | |
| CN113476659B (zh) | 一种人工生物瓣膜处理方法 | |
| CN111467574A (zh) | 基于edc/nhs活化和重组人源胶原蛋白修饰的生物瓣膜材料及其制备方法 | |
| CN111658825B (zh) | 一种具有长效抗血栓性能的瓣膜材料及其制备方法 | |
| CN105194733A (zh) | 一种化学处理人工瓣膜的方法 | |
| CN111514375B (zh) | 一种抗钙化生物瓣膜材料及其制备方法 | |
| CN112263715B (zh) | 一种抗凝血抗钙化的人工心脏瓣膜材料及其制备方法与应用 | |
| CN112773936A (zh) | 一种改性心包膜及其制备方法、人工心脏瓣膜假体 | |
| KR20010038098A (ko) | 헤파린 처리된 항석회화성 생체조직 이식물 및 이의 제조 방법 | |
| CN113952513B (zh) | 一种抗衰败人工生物瓣膜及其制备方法和应用 | |
| CN111617317B (zh) | 一种生物组织的交联固定方法 | |
| CN116983476A (zh) | 一种纳米结构低免疫原性生物型人工血管及其制备方法 | |
| CN111317866A (zh) | 一种重组人源ⅲ型胶原蛋白修饰的生物瓣膜材料及其制备方法 | |
| CN117159808A (zh) | 一种复合交联生物瓣膜 | |
| CN118059314A (zh) | 组合型人工心脏瓣膜及其制备方法 | |
| Murabayashi et al. | Biolized Material for Cardiac Prosthesis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20220818 Address after: 130013 No. 11111, Haoyue Road, Luyuan District, Changchun City, Jilin Province (Room 101, office building of Jilin Changchun Haoyue Halal Meat Industry Co., Ltd.) Patentee after: Jilin Qiming Haoyue Biotechnology Co.,Ltd. Address before: 610064, No. 24, south section of first ring road, Chengdu, Sichuan, Wuhou District Patentee before: SICHUAN University |
|
| TR01 | Transfer of patent right | ||
| PP01 | Preservation of patent right |
Effective date of registration: 20240319 Granted publication date: 20210330 |
|
| PP01 | Preservation of patent right |